Table 3.
Odds of having high HDL-C levels (70 mg/dL ≤ HDL-C) compared to having low HDL-C (< 40 mg/dL in men and < 50 mg/dL in women) in the studied population with type 2 diabetes according to the multivariate models
| Multivariate | OR | 95% CI | p-value | |
|---|---|---|---|---|
| Model 1a | ||||
| Height | 0.918 | 0.866–0.974 | 0.004 | |
| SBP | 0.941 | 0.910–0.972 | < 0.001 | |
| Vitamin D | 0.970 | 0.941–0.999 | 0.047 | |
| Triglyceride | 0.992 | 0.987–0.998 | 0.008 | |
| Model 2b | ||||
| Height in category | Height < 160 cm | 1.00 (reference) | ||
| Height ≥ 160 cm | 0.277 | 0.127–0.607 | 0.001 | |
| SBP in category | SBP < 130 mmHg | 1.00 (reference) | ||
| SBP ≥ 130 mmHg | 0.387 | 0.190–0.789 | 0.009 | |
| Vitamin D in category | Vitamin D < 30 ng/mL | 1.00 (reference) | ||
| Vitamin D ≥ 30 ng/mL | 0.422 | 0.205–0.869 | 0.019 | |
| Triglyceride in category | Triglyceride < 150 mg/dL | 1.00 (reference) | ||
| Triglyceride ≥ 150 mg/dL | 0.352 | 0.153–0.807 | 0.013 | |
OR: odds ratio, 95% CI: 95% confidence interval
SBP: systolic blood pressure, HDL-C: high density lipoprotein cholesterol
aModel 1 was adjusted for height, waist circumference, SBP, Vitamin D, HBA1c, the status of hypertensive drugs, the anti-diabetic drugs, the type of lipid-lowering drug, duration of diabetes, creatinine, and triglyceride concentration
bModel 2 was adjusted for height, SBP, Vitamin D, the status of hypertensive drugs, the anti-diabetic drugs, the type of lipid-lowering drug, duration of diabetes, and triglyceride concentration after dividing into different categories